Placenta extract injection aims to tame chronic liver disease
NCT ID NCT06493799
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests a drug called LAENNEC, made from human placenta, in people with chronic liver disease. It compares giving the drug as an intravenous drip versus a standard shot under the skin. The main goal is to see if the IV form lowers liver enzyme levels more effectively over 6 weeks. About 226 adults with alcoholic or non-alcoholic fatty liver disease and elevated ALT levels are being recruited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LAENNEC (human placenta hydrolysate)
What this could lead to
If successful, this could offer a new way to deliver LAENNEC intravenously to better manage chronic liver disease and reduce liver enzyme levels.
What could go wrong
This is a Phase 3 trial, but it compares two forms of the same drug, not against a placebo. The benefit over standard care is unclear, and long-term outcomes are not measured.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-ALCOHOLIC FATTY LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
GC wellbeing
RECRUITINGYongin-si, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••